US4810643A
(en)
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
US4933447A
(en)
|
1987-09-24 |
1990-06-12 |
Ss Pharmaceutical Co., Ltd. |
Quinoline derivatives
|
US5021409A
(en)
|
1989-12-21 |
1991-06-04 |
Johnson Matthey Plc |
Antiviral cyclic polyamines
|
US6001826A
(en)
|
1989-12-21 |
1999-12-14 |
Anormed, Inc. |
Chemical compounds
|
GB9126677D0
(en)
|
1991-12-16 |
1992-02-12 |
Johnson Matthey Plc |
Improvements in chemical compounds
|
GB9200245D0
(en)
|
1992-01-07 |
1992-02-26 |
British Bio Technology |
Compounds
|
US5235056A
(en)
|
1992-04-22 |
1993-08-10 |
Ciba-Geigy Corporation |
Substituted 1-hydroxy-2,6-diaryl-4-piperidone ketals and polymer compositions stabilized therewith
|
GB9400411D0
(en)
|
1994-01-11 |
1994-03-09 |
Johnson Matthey Plc |
Improvements in chemical compounds
|
GB9511357D0
(en)
|
1995-06-06 |
1995-08-02 |
Johnson Matthey Plc |
Improved antiviral compounds
|
US6506770B1
(en)
|
1996-06-06 |
2003-01-14 |
Anormed, Inc. |
Antiviral compounds
|
WO1997009976A2
(en)
|
1995-09-01 |
1997-03-20 |
Washington University |
Method of reducing neurotoxic injury with zinc chelators
|
CA2249401A1
(en)
|
1996-03-22 |
1997-09-25 |
The Dupont Merck Pharmaceutical Company |
Novel asymmetric synthesis of r-.alpha.-propyl-piperonyl amine and its analogs
|
AU740603B2
(en)
|
1997-06-02 |
2001-11-08 |
Janssen Pharmaceutica N.V. |
(imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
|
AU8576098A
(en)
|
1997-07-25 |
1999-02-16 |
Merck & Co., Inc. |
Cyclic amine modulators of chemokine receptor activity
|
KR20010015639A
(en)
|
1997-09-30 |
2001-02-26 |
스즈키 다다시 |
Sulfonyl derivatives
|
GB9726229D0
(en)
|
1997-12-12 |
1998-02-11 |
Zeneca Ltd |
Resolution of chiral amines
|
KR20010032841A
(en)
|
1997-12-19 |
2001-04-25 |
다케다 야쿠힌 고교 가부시키가이샤 |
Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative
|
US6607799B1
(en)
|
1998-10-15 |
2003-08-19 |
3M Innovative Properties Company |
Surgical dressing with delivery system and method of manufacture
|
US6635278B1
(en)
|
1998-12-15 |
2003-10-21 |
Gilead Sciences, Inc. |
Pharmaceutical formulations
|
US6365583B1
(en)
|
1999-02-02 |
2002-04-02 |
Anormed, Inc. |
Methods to enhance white blood cell count
|
CZ20013421A3
(en)
|
1999-03-24 |
2002-03-13 |
Anormed Inc. |
Heterocyclic compounds binding chemokine receptors
|
US6245799B1
(en)
|
1999-11-08 |
2001-06-12 |
American Home Products Corp |
[(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
|
US6602872B1
(en)
|
1999-12-13 |
2003-08-05 |
Merck & Co., Inc. |
Substituted pyridazines having cytokine inhibitory activity
|
US6683192B2
(en)
|
2000-03-30 |
2004-01-27 |
Curis, Inc. |
Small organic molecule regulators of cell proliferation
|
PE20020354A1
(en)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS
|
AU2001293551B2
(en)
|
2000-09-15 |
2007-08-23 |
Anormed Inc. |
Chemokine receptor binding heterocyclic compounds
|
AU9156901A
(en)
|
2000-09-15 |
2002-03-26 |
Anormed Inc |
Chemokine receptor binding heterocyclic compounds
|
ES2269465T3
(en)
|
2000-09-15 |
2007-04-01 |
Anormed Inc |
HETEROCICLICAL COMPOUNDS OF UNION TO CHEMIOQUINE RECEPTORS.
|
CZ20031910A3
(en)
|
2000-12-11 |
2003-12-17 |
Tularik Inc. |
Compound exhibiting CXCR3 antagonistic activity and pharmaceutical preparation
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
GB0107228D0
(en)
|
2001-03-22 |
2001-05-16 |
Astrazeneca Ab |
Chemical compounds
|
PT1389617E
(en)
|
2001-04-27 |
2007-04-30 |
Zenyaku Kogyo Kk |
Heterocyclic compound and antitumor agent containing the same as active ingredient
|
US6794379B2
(en)
|
2001-06-06 |
2004-09-21 |
Tularik Inc. |
CXCR3 antagonists
|
ATE538785T1
(en)
|
2001-07-31 |
2012-01-15 |
Genzyme Global S A R L |
METHOD FOR MOBILIZING PROCURSIONS/STEM CELLS
|
US7169750B2
(en)
|
2001-07-31 |
2007-01-30 |
Anormed, Inc. |
Methods to mobilize progenitor/stem cells
|
US8178123B2
(en)
|
2001-08-29 |
2012-05-15 |
Femina Pharma Incorporated |
Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
|
US20030055876A1
(en)
*
|
2001-08-29 |
2003-03-20 |
Aravinda Korala |
Printing web content from self-service kiosks
|
CN101353324A
(en)
|
2001-09-12 |
2009-01-28 |
阿诺麦德股份有限公司 |
Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
|
EP1465889B1
(en)
*
|
2001-12-21 |
2017-03-22 |
Genzyme Corporation |
Chemokine receptor binding heterocyclic compounds with enhanced efficacy
|
US7354932B2
(en)
|
2001-12-21 |
2008-04-08 |
Anormed, Inc. |
Chemokine receptor binding heterocyclic compounds with enhanced efficacy
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
US7491544B2
(en)
|
2002-05-20 |
2009-02-17 |
New York University |
Chiral piperidine and quinucledine ligands
|
CN1674929B
(en)
|
2002-08-14 |
2013-07-17 |
赛伦斯治疗公司 |
Use of protein kinase N beta
|
JP4666256B2
(en)
|
2002-12-10 |
2011-04-06 |
小野薬品工業株式会社 |
Nitrogen-containing heterocyclic compound and pharmaceutical use thereof
|
KR20070087266A
(en)
|
2003-04-03 |
2007-08-28 |
세마포르 파머슈티컬즈, 아이엔씨. |
Pi-3 kinase inhibitor prodrugs
|
EP1613613B1
(en)
|
2003-04-11 |
2021-06-02 |
Genzyme Corporation |
Cxcr4 chemokine receptor binding compounds
|
AU2004232361A1
(en)
|
2003-04-22 |
2004-11-04 |
Anormed Inc. |
Chemokine receptor binding heterocyclic compounds with enhanced efficacy
|
US7501518B2
(en)
|
2003-04-22 |
2009-03-10 |
Genzyme Corporation |
Methods of making 2,6-diaryl piperidine derivatives
|
EP1644363B1
(en)
|
2003-05-30 |
2012-02-22 |
Gemin X Pharmaceuticals Canada Inc. |
Triheterocyclic compounds, compositions, and methods for treating cancer
|
US7173015B2
(en)
|
2003-07-03 |
2007-02-06 |
The Trustees Of The University Of Pennsylvania |
Inhibition of Syk kinase expression
|
US7498346B2
(en)
|
2003-12-11 |
2009-03-03 |
Genzyme Corporation |
Chemokine receptor binding compounds
|
RU2006136381A
(en)
*
|
2004-03-15 |
2008-04-27 |
Анормед, Инк. (Ca) |
METHOD FOR PRODUCING AN ANTAGONIST CXCR4
|
CA2561718A1
(en)
|
2004-04-13 |
2005-10-27 |
Icagen, Inc. |
Polycyclic pyridines as potassium ion channel modulators
|
DE102004021716A1
(en)
|
2004-04-30 |
2005-12-01 |
Grünenthal GmbH |
Substituted imidazo [1,2-a] pyridine compounds and drugs containing substituted imidazo [1,2-a] pyridine compounds
|
LT2612862T
(en)
|
2004-05-13 |
2017-01-25 |
Icos Corporation |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
|
MX2007001514A
(en)
|
2004-08-02 |
2007-03-27 |
Smithkline Beecham Corp |
Chemical compounds.
|
TW200619217A
(en)
|
2004-08-16 |
2006-06-16 |
Smithkline Beecham Corp |
Chemical compounds
|
WO2006026703A2
(en)
|
2004-09-02 |
2006-03-09 |
Smithkline Beecham Corporation |
Chemical compounds
|
WO2006036816A2
(en)
|
2004-09-24 |
2006-04-06 |
Smithkline Beecham Corporation |
Chemical compounds
|
TW200619206A
(en)
|
2004-09-29 |
2006-06-16 |
Anormed Inc |
Chemokine-binding heterocyclic compound salts, and methods of use thereof
|
EP1856135B1
(en)
|
2005-01-19 |
2009-12-09 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
WO2006096444A2
(en)
|
2005-03-04 |
2006-09-14 |
Smithkline Beecham Corporation |
Chemical compounds
|
PL2757099T3
(en)
|
2005-05-12 |
2018-02-28 |
Abbvie Bahamas Limited |
Apoptosis promoters
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
DE602006015966D1
(en)
|
2005-07-08 |
2010-09-16 |
Siemens Healthcare Diagnostics |
METHOD FOR PREDICTING AND MONITORING AN IMMEDIATE RESPONSE TO CANCER THERAPY
|
JP2009500451A
(en)
|
2005-07-11 |
2009-01-08 |
スミスクライン ビーチャム コーポレーション |
Pyranopyridine compound
|
US7402325B2
(en)
|
2005-07-28 |
2008-07-22 |
Phoenix Biotechnology, Inc. |
Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
|
CN101277981B
(en)
|
2005-08-02 |
2014-07-09 |
英尼奥斯欧洲有限公司 |
Diene polymerisation
|
AU2006280945A1
(en)
|
2005-08-19 |
2007-02-22 |
Genzyme Corporation |
Methods to enhance chemotherapy
|
WO2007027999A2
(en)
|
2005-08-31 |
2007-03-08 |
Smithkline Beecham Corporation |
Chemical compounds
|
EP1931645B1
(en)
|
2005-10-07 |
2014-07-16 |
Exelixis, Inc. |
N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
|
CN103626742B
(en)
|
2005-11-01 |
2017-04-26 |
塔格根公司 |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
US8168783B2
(en)
|
2005-11-18 |
2012-05-01 |
Ono Pharmaceutical Co., Ltd. |
Chemokine receptor antagonists and use thereof
|
AR063656A1
(en)
|
2005-11-30 |
2009-02-11 |
Schering Corp |
COMPOSITIONS THAT INCLUDE A COMBINATION OF ANTAGONISTS OF CCR5 AND CXCR4
|
ES2612196T3
(en)
|
2005-12-13 |
2017-05-12 |
Incyte Holdings Corporation |
Pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines substituted with heteroaryl as Janus kinase inhibitors
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
PI-3 Kinase inhibitors and methods of their use
|
WO2007087548A2
(en)
|
2006-01-25 |
2007-08-02 |
Smithkline Beecham Corporation |
Chemical compounds
|
TW200738711A
(en)
|
2006-01-25 |
2007-10-16 |
Smithkline Beecham Corp |
Chemical compounds
|
GB0605786D0
(en)
|
2006-03-22 |
2006-05-03 |
Glaxo Group Ltd |
Compounds
|
RU2439074C2
(en)
|
2006-04-26 |
2012-01-10 |
Ф. Хоффманн-Ля Рош Аг |
THIENO[3,2-d]PYRIMIDINE DERIVATIVE AS PHOSPHATIDYL INOSITOL-3-KINASE (PI3K) INHIBITOR
|
US20070259040A1
(en)
|
2006-05-01 |
2007-11-08 |
Cherukuri S R |
Novel triptan formulations and methods for making them
|
MX2008014296A
(en)
|
2006-06-12 |
2009-03-06 |
Pfizer Prod Inc |
Pharmaceuticals.
|
TWI482772B
(en)
|
2006-08-21 |
2015-05-01 |
Astrazeneca Ab |
Compositions, suitable for oral administration, comprising a triazolo(4,5-d)pyrimidin derivate
|
SI2526933T1
(en)
|
2006-09-22 |
2015-07-31 |
Pharmacyclics, Inc. |
Inhibitors of Bruton's tyrosine kinase
|
EP3023422A1
(en)
|
2007-03-12 |
2016-05-25 |
YM BioSciences Australia Pty Ltd |
Phenyl amino pyrimidine compounds and uses thereof
|
WO2008118802A1
(en)
|
2007-03-23 |
2008-10-02 |
Regents Of The University Of Minnesota |
Therapeutic compounds
|
EP2155747B1
(en)
|
2007-05-10 |
2012-10-24 |
GE Healthcare Limited |
Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors
|
PE20090717A1
(en)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
|
WO2009026251A1
(en)
|
2007-08-17 |
2009-02-26 |
The General Hospital Corporation |
Detecting ions and measuring ion concentrations
|
US9101628B2
(en)
|
2007-09-18 |
2015-08-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and composition of treating a flaviviridae family viral infection
|
MX2010010012A
(en)
|
2008-03-11 |
2010-10-20 |
Incyte Corp |
Azetidine and cyclobutane derivatives as jak inhibitors.
|
EP2254597A4
(en)
|
2008-03-20 |
2012-04-18 |
Carolus Therapeutics Inc |
Methods of treatment using anti-mif antibodies
|
AU2009228034A1
(en)
|
2008-03-28 |
2009-10-01 |
Altiris Therapeutics |
Chemokine receptor modulators
|
WO2009151910A2
(en)
|
2008-05-25 |
2009-12-17 |
Wyeth |
Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
JP2010016628A
(en)
|
2008-07-03 |
2010-01-21 |
Canon Inc |
Image processing device and image processing method
|
PT2364314E
(en)
|
2008-12-09 |
2014-06-09 |
Gilead Sciences Inc |
Modulators of toll-like receptors
|
US9119790B2
(en)
|
2009-09-28 |
2015-09-01 |
Zenbury International Limited |
Pharmaceutical composition
|
US20110290821A1
(en)
|
2010-05-28 |
2011-12-01 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Anti-viral compositions and methods for administration
|
CA2706292A1
(en)
|
2010-05-28 |
2011-11-28 |
Pharmascience Inc. |
A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
|
US9155723B2
(en)
|
2010-06-28 |
2015-10-13 |
The General Hospital Corporation |
Anti-CXCR4 as a sensitizer to cancer therapeutics
|
GB201017345D0
(en)
|
2010-10-14 |
2010-11-24 |
Proximagen Ltd |
Receptor antagonists
|
US9267934B2
(en)
|
2010-10-26 |
2016-02-23 |
University Of South Alabama |
Methods and compositions for ameliorating pancreatic cancer
|
AU2011336397B2
(en)
|
2010-12-03 |
2016-12-15 |
Emory University |
Chemokine CXCR4 receptor modulators and uses related thereto
|
WO2012078633A2
(en)
|
2010-12-07 |
2012-06-14 |
Philadelphia Health And Education Corporation, D/B/A Drexel University College Of Medicene |
Methods of inhibiting metastasis from cancer
|
CN107699585A
(en)
|
2010-12-09 |
2018-02-16 |
宾夕法尼亚大学董事会 |
The purposes of the T cell treating cancer of Chimeric antigen receptor modification
|
AU2012206945B2
(en)
|
2011-01-11 |
2015-02-19 |
Dimerix Bioscience Pty Ltd |
Combination therapy
|
BR112013029482A2
(en)
|
2011-05-16 |
2016-08-09 |
Genzyme Corp |
use of cxr4 antagonists
|
AR087364A1
(en)
|
2011-07-29 |
2014-03-19 |
Pf Medicament |
ANTI-CXCR4 ANTIBODY AND ITS USE FOR CANCERES DETECTION AND DIANOSTIC
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
WO2013106732A1
(en)
|
2012-01-12 |
2013-07-18 |
Gilead Sciences, Inc. |
Pharmaceutical compositions and methods for their preparation
|
US20150301058A1
(en)
|
2012-11-26 |
2015-10-22 |
Caris Science, Inc. |
Biomarker compositions and methods
|
US10064826B2
(en)
|
2013-03-15 |
2018-09-04 |
Navinta, Llc |
Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process
|
EP3473299A1
(en)
|
2013-06-05 |
2019-04-24 |
Salk Institute for Biological Studies |
Vitamin d receptor agonists to treat diseases involving cxcl12 activity
|
WO2015019284A2
(en)
|
2013-08-05 |
2015-02-12 |
Cambridge Enterprise Limited |
Inhibition of cxcr4 signaling in cancer immunotherapy
|
PT3650014T
(en)
|
2013-08-27 |
2021-12-27 |
Gilead Pharmasset Llc |
Combination formulation of two antiviral compounds
|
AU2014318614B2
(en)
|
2013-09-12 |
2021-01-07 |
Dana-Farber Cancer Institute Inc. |
Methods for evaluating and treating Waldenstrom's macroglobulinemia
|
US20150273033A1
(en)
|
2013-11-05 |
2015-10-01 |
Cognate Bioservices, Inc. |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
WO2015143092A1
(en)
|
2014-03-18 |
2015-09-24 |
The Research Foundation For The State University Of New York |
Therapeutic agent for treating tumors
|
JP6701088B2
(en)
|
2014-03-19 |
2020-05-27 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
Heterocyclic compounds for use in the treatment of PI3K-gamma mediated disorders
|
EP3157921A1
(en)
|
2014-06-23 |
2017-04-26 |
Dr. Reddy's Laboratories Ltd. |
Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain
|
PL3169341T3
(en)
|
2014-07-16 |
2019-12-31 |
Transgene Sa |
Oncolytic virus for expression of immune checkpoint modulators
|
KR20170105514A
(en)
|
2014-12-12 |
2017-09-19 |
커먼웰쓰 사이언티픽 앤 인더스트리알 리서치 오거니제이션 |
Dislodgement and release of hsc using alpha 9 integrin antagonist and cxcr4 antagonist
|
US20180133327A1
(en)
|
2015-03-16 |
2018-05-17 |
Amal Therapeutics Sa |
Cell Penetrating Peptides and Complexes Comprising the Same
|
CA2989144A1
(en)
|
2015-06-12 |
2016-12-15 |
Bristol-Myers Squibb Company |
Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
|
EP3350183A1
(en)
|
2015-09-14 |
2018-07-25 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
|
US10379661B2
(en)
|
2015-09-25 |
2019-08-13 |
Samsung Electronics Co., Ltd. |
Coordinate measuring apparatus and coordinate measuring system having the same
|
WO2017106332A1
(en)
|
2015-12-14 |
2017-06-22 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
JP6864296B2
(en)
|
2015-12-14 |
2021-04-28 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
How to treat cancer
|
DK3393468T3
(en)
|
2015-12-22 |
2022-12-19 |
X4 Pharmaceuticals Inc |
Methods for treating an immunodeficiency disease
|
CA3010617A1
(en)
|
2016-01-22 |
2017-07-27 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
WO2017177230A1
(en)
|
2016-04-08 |
2017-10-12 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
KR102548385B1
(en)
|
2016-04-14 |
2023-06-28 |
크리에티브이 마이크로테크, 인크. |
Methods of using pd-l1 expression in treatment decisions for cancer therapy
|
CN109641838A
(en)
|
2016-06-21 |
2019-04-16 |
X4 制药有限公司 |
CXCR4 inhibitor and application thereof
|
EP3471727B1
(en)
|
2016-06-21 |
2020-12-09 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
JP7084624B2
(en)
|
2016-06-21 |
2022-06-15 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
CXCR4 inhibitor and its use
|
CN110996952A
(en)
|
2017-06-21 |
2020-04-10 |
X4 制药有限公司 |
Methods for treating cancer
|
US20210349099A1
(en)
|
2017-11-07 |
2021-11-11 |
X4 Pharmaceuticals, Inc. |
Cancer biomarkers and methods of use thereof
|
JP2021506838A
(en)
|
2017-12-19 |
2021-02-22 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
Acyclic CXCR4 Inhibitors and Their Use
|
WO2019200223A1
(en)
|
2018-04-13 |
2019-10-17 |
X4 Pharmaceuticals, Inc. |
Cancer serum biomarkers and methods of use thereof
|
US10548889B1
(en)
*
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|